These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32219955)

  • 21. Secukinumab Self-Administration by Prefilled Syringe Maintains Reduction of Plaque Psoriasis Severity Over 52 Weeks: Results of the FEATURE Trial.
    Gottlieb AB; Blauvelt A; Prinz JC; Papanastasiou P; Pathan R; Nyirady J; Fox T; Papavassilis C
    J Drugs Dermatol; 2016 Oct; 15(10):1226-1234. PubMed ID: 27741340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Secukinumab treatment and vaccination efficacy.
    Mohammed A; Singh R; Feldman SR
    Clin Exp Dermatol; 2022 Apr; 47(4):750-751. PubMed ID: 34747527
    [No Abstract]   [Full Text] [Related]  

  • 23. Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab.
    Morita A; Tani Y; Matsumoto K; Yamaguchi M; Teshima R; Ohtsuki M
    J Dermatol; 2020 May; 47(5):452-457. PubMed ID: 32173900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
    Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
    J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful secukinumab treatment in focal segmental glomerulosclerosis associated with plaque psoriasis.
    Cao Z; Liu Z; Zhu X; Yang Q; Xu Q; Zhang C
    Ren Fail; 2022 Dec; 44(1):826-830. PubMed ID: 35546261
    [No Abstract]   [Full Text] [Related]  

  • 26. Successful treatment of secukinumab-resistant palmoplantar pustulosis by Dupilumab: A case report.
    Zheng YX; Zheng M; Cai SQ
    Dermatol Ther; 2022 Nov; 35(11):e15781. PubMed ID: 35986706
    [No Abstract]   [Full Text] [Related]  

  • 27. Family history of psoriasis: a novel protective factor for therapy switch in patients treated with Secukinumab or Ixekizumab.
    Manzo Margiotta F; Michelucci A; Panduri S; Tonini A; Davini G; Romanelli M; Morganti R; Dini V
    J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):e454-e456. PubMed ID: 35048437
    [No Abstract]   [Full Text] [Related]  

  • 28. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial.
    Bodemer C; Kaszuba A; Kingo K; Tsianakas A; Morita A; Rivas E; Papanastasiou P; Keefe D; Patekar M; Charef P; Zhang L; Cafoncelli S; Papavassilis C
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):938-947. PubMed ID: 33068444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study.
    Reich K; Puig L; Szepietowski JC; Paul C; Lacour JP; Tsianakas A; Sieder C; Rissler M; Pournara E; Orsenigo R
    Br J Dermatol; 2020 Feb; 182(2):304-315. PubMed ID: 31102257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical experience of ixekizumab in the treatment of patients with history of chronic erythrodermic psoriasis who failed secukinumab: a case series.
    Lo Y; Tsai TF
    Br J Dermatol; 2019 Nov; 181(5):1106-1107. PubMed ID: 31145806
    [No Abstract]   [Full Text] [Related]  

  • 31. Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: A double-blind, randomized-withdrawal, placebo-controlled study.
    Dogra S; D S K; Budamakuntla L; Srinivas CR; Khopkar U; Gupta S; Shetty N; Pratap DV; Gopal MG; Rao TN; Garg V; Sumathy TK; Saraswat A; Bhat R; Kura M; Pandey N; Shah R; Sai Krishna K; Padmaja D; Manmohan G; M S R; Barve A; Montero E
    J Am Acad Dermatol; 2015 Aug; 73(2):331-3.e1. PubMed ID: 26183983
    [No Abstract]   [Full Text] [Related]  

  • 32. Real-world data on the clinical use of secukinumab in pediatric generalized pustular psoriasis: A 48-week retrospective study.
    Ruan SF; Zhang LL; Liu Z; Lin TT; Wang HQ; Xu QY; Xiang N; Cheng B; Liu T; Ha HY; Gong T; Ji C
    J Am Acad Dermatol; 2023 Jan; 88(1):243-246. PubMed ID: 35588923
    [No Abstract]   [Full Text] [Related]  

  • 33. Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis.
    Gisondi P; Rovaris M; Piaserico S; Girolomoni G
    Br J Dermatol; 2020 Jan; 182(1):175-179. PubMed ID: 31004509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and safety of secukinumab in patients with moderate-severe psoriasis: A multicenter real-life study.
    Carpentieri A; Mascia P; Fornaro M; Beylot-Barry M; Taieb A; Foti C; Loconsole F
    Dermatol Ther; 2020 Nov; 33(6):e14044. PubMed ID: 32697028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis.
    Cai L; Zhang JZ; Yao X; Gu J; Liu QZ; Zheng M; Zhang SF; Xu JH; Li CX; Cheng H; Guo Q; Pan WL; Li SQ; Li RY; Guo ZP; Song ZQ; Li SS; Dong XQ; Wang L; Fu R; Regnault P; Charef P; Mazur R; Patekar M
    Chin Med J (Engl); 2020 Nov; 133(22):2665-2673. PubMed ID: 33060370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis.
    Van Muijen ME; Thomas SE; Vellinga D; Bouwman S; Van Doorn MBA; Politiek K; Otero ME; Van den Reek JMPA; De Jong EMGJ
    Acta Derm Venereol; 2022 Aug; 102():adv00755. PubMed ID: 35788690
    [No Abstract]   [Full Text] [Related]  

  • 37. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: results from extension phase of the SUPREME study.
    Papini M; Cusano F; Romanelli M; Burlando M; Stinco G; Girolomoni G; Peris K; Potenza C; Offidani A; Bartezaghi M; Aloisi E; Costanzo A;
    Br J Dermatol; 2019 Aug; 181(2):413-414. PubMed ID: 31001812
    [No Abstract]   [Full Text] [Related]  

  • 38. A Case of Ixekizumab-induced Psoriasiform Eruption.
    Oiwa T; Fujita M; Takase S; Nishimura Y; Ota M; Okada K; Tachibana T
    Acta Derm Venereol; 2019 Apr; 99(4):446-447. PubMed ID: 30723870
    [No Abstract]   [Full Text] [Related]  

  • 39. Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results.
    Augustin M; Dauden E; Mrowietz U; Konstantinou MP; Gerdes S; Kingo K; Szepietowski JC; Perrot JL; Cuccia A; Rissler M; Gathmann S; Sieder C; Orsenigo R; Jagiello P; Bachhuber T
    J Eur Acad Dermatol Venereol; 2021 Feb; 35(2):431-440. PubMed ID: 32426889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methotrexate vs secukinumab safety in psoriasis patients with metabolic syndrome.
    Gisondi P; Bellinato F; Bruni M; De Angelis G; Girolomoni G
    Dermatol Ther; 2020 Nov; 33(6):e14281. PubMed ID: 32888370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.